The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGuangdong Association of Clinical Trials
About this trial
Several published clinical trials have shown the superiority of immunotherapy in neoadjuvant setting. Here we conducted this real world study to see whether neoadjuvant immunotherapy would bring MPR and survival benefits in NSCLC, for example, single agent immunotherapy or immunotherapy combination with chemotherapy. Furthermore biomarker analysis would be also performed to achieve personalized neoadjuvant immunotherapy.
Eligibility criteria
Qualifiers
Written informed consent provided
Males or females aged ≥18 years
Able to comply with the required protocol and follow-up procedures、
Pathologically diagnosed of potentially resectable non-small cell lung cancer with stage II-IIIA (TNM 8th edition)
Disqualifiers
EGFR mutation (+) or ALK translocation (+)
Active Central nervous system (CNS) metastases
Patients with active, known or suspected autoimmune disease.
Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement or unexpected conditions of recurrence in the absence of an external trigger are allowed to be included
Trial design
Treatments tested in this trial
- Immunotherapy
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov